Systematic Review and Meta-Analysis of Randomized Controlled Trials of Xingnaojing Treatment for Stroke

Abstract EN

Objective.

Xingnaojing injection (XNJ) is a well-known traditional Chinese patent medicine (TCPM) for stroke.

The aim of this study is to assess the efficacy of XNJ for stroke including ischemic stroke, intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH).

Methods.

An extensive search was performed within using eight databases up to November 2013.

Randomized controlled trials (RCTs) on XNJ for treatment of stroke were collected.

Study selection, data extraction, quality assessment, and meta-analysis were conducted according to the Cochrane standards, and RevMan5.0 was used for meta-analysis.

Results.

This review included 13 RCTs and a total of 1,514 subjects.

The overall methodological quality was poor.

The meta-analysis showed that XNJ combined with conventional treatment was more effective for total efficacy, neurological deficit improvement, and reduction of TNF-α levels compared with those of conventional treatment alone.

Three trials reported adverse events, of these one trial reported mild impairment of kidney and liver function, whereas the other two studies failed to report specific adverse events.

Conclusion.

Despite the limitations of this review, we suggest that XNJ in combination with conventional medicines might be beneficial for the treatment of stroke.

Currently there are various methodological problems in the studies.

Therefore, high-quality, large-scale RCTs are urgently needed.